Call for Abstract
13th International Conference on Genomics and Molecular Biology, will be organized around the theme “Advances in Genome & Molecular Biology Evolution Technologies ”
Genomics 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Genomics 2020
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Genomics is the investigation of genomes, the entire arrangement of hereditary material inside a life form. Genomics includes the sequencing and examination of genomes. Genomics is additionally worried about the structure, capacity, examination, and advancement of genomes. As opposed to hereditary qualities, which alludes to the investigation of individual qualities and their parts in legacy, genomics utilizes high throughput DNA sequencing and bioinformatics to amass, and examine the capacity and structure of whole genomes.
- Track 1-1Genome analysis
- Track 1-2Metagenomics
- Track 1-3Epigenomics
Cancer Genomics is the study of genetic mutations responsible for cancer, using genome sequencing and bioinformatics. Clinical genomics is to improve cancer treatment and outcomes lies in determining which sets of genes and gene interactions affect different subsets of cancers. International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers.
- Track 2-1Cancer Therapy
- Track 2-2Comparative oncogenomics
- Track 2-3Cancer Mutagenesis
Molecular biology concerns the molecular basis of biological activity between the various systems of a cell, including the interactions between the different types of DNA, RNA and proteins and their biosynthesis, and studies how these interactions are regulated. It has many applications like in gene finding, molecular mechanisms of diseases and its therapeutic approaches by cloning, expression and regulation of gene. Research area includes gene expression, epigenetics and chromatin structure and function, RNA processing, functions of non-coding RNAs, transcription. Nowadays, Most advaced researches are going on these topics: Molecular biology, DNA replication, repair and recombination, Transcription, RNA processing, Post-translational modification, proteomics, Mutation, Site-directed mutagenesis, Epigeneticschromatin structure and function
- Track 3-1Molecular Cloning
- Track 3-2Immunology
- Track 3-3Biomolecules
- Track 3-4Developmental biology
National Science Foundation (NSF) announces its intention to continue to support plant genome research through the Plant Genome Research Program (PGRP). Plant Genomics Research Program (PGRP) awards from the National Science Foundation (NSF) that NSF offers supplements to support research collaboration with scientist sin developing countries. The intent of Developing Country Collaborations in Plant Genome Research (DCC-PGR) awards is to support collaborative research linking U.S. researchers with partners from developing countries to solve problems of mutual interest in agriculture, energy and the environment, while placing U.S. and international researchers at the center of a global network of scientific excellence.
- Track 4-1Plant Pathology
- Track 4-2Plant Developmental Biology
- Track 4-3Plant Ecology
Stem cell, an undifferentiated cell that can partition to deliver some posterity cells that proceed as stem cells and a few cells that are bound to separate. Stem cells are a progressing wellspring of the separated cells that make up the tissues and organs of creatures and plants.
- Track 5-1Stem Cell Therapy.
- Track 5-2Stem Cell Research
- Track 5-3Embryonic stem cells
Structural biology is a part of molecular biology, biochemistry, and biophysics worried about the molecular structure of organic macromolecules (particularly proteins, made up of amino acids, RNA or DNA, made up of nucleotides, layers, made up of lipids) how they procure the structures they have, and how adjustments in their structures influence their capacity. This subject is of incredible enthusiasm to scientists since macromolecules do the vast majority of the elements of cells, and it is just by snaking into explicit three-dimensional shapes that they can play out these capacities. This design, the "tertiary structure" of particles, depends in a confounded route on every atom's essential sythesis, or "essential structure."
Biomolecules are too little to even consider seeing in detail even with the most exceptional light magnifying instruments. The techniques that auxiliary scholars use to decide their structures by and large include estimations on tremendous quantities of indistinguishable atoms simultaneously.
- Track 6-1Proteolysis
- Track 6-2Molecular Model
- Track 6-3Structural genomics
The human genome is the finished arrangement of nucleic corrosive successions for people, encoded as DNA inside the 23 chromosome combines in cell cores and in a little DNA particle found inside individual mitochondria. These are typically treated independently as the atomic genome, and the mitochondrial genome.
- Track 7-1Completeness of the human genome sequence
- Track 7-2Mitochondrial DNA
- Track 7-3Human genetic disorders
Clinical Genomics is the use of genome sequencing to inform patient diagnosis and care. The California Initiative to Advance Precision Medicine has just been launched, and it is being headed by UCSF’s high profile recent hire, Atul Butte.
The global market for Clinical Genomics is expected to reach USD 22.1 billion by 2020, growing at an estimated CAGR of 10.3% from 2014 to 2020, according to a new study by Grand View Research.
Genomic healthcare uses many pieces of genetic information to refine diagnoses, individualize treatments, prevent adverse drug effects, manage epidemics and develop new therapies. The incorporation of whole-genome and whole-exome sequencing into clinical practice will undoubtedly change the way genetic counselors and other clinicians approach genetic testing. Genomics play an imperative role in the field of infectious disease testing by enabling the use of fast and effective result rendering molecular diagnostic tests. Genomics based diagnostics dominated the overall market in terms of revenue at 36.4% in 2013 majorly owing to the presence of a relatively larger number of R&D programs.
- Track 8-1Genome sequencing
- Track 8-2Genomic data
Cell Biology is the investigation of cell structure and capacity, and it rotates around the idea that the cell is the principal unit of life. Concentrating on the cell allows a point by point comprehension of the tissues and life forms that cells make.
- Track 9-1Cell Metabolism
- Track 9-2Cell communication and signaling
- Track 9-3Cell cycle
Bioinformatics the science of collecting and analyzing complex biological data such as genetic codes. Molecular medicine requires the integration and analysis of genomic, molecular, cellular, as well as clinical data and it thus offers a remarkable set of challenges to bioinformatics. Bioinformatics nowadays has an essential role both, in deciphering genomic, transcriptomic, and proteomic data generated by high-throughput experimental technologies, and in organizing information gathered from traditional biology and medicine. Research Centers for Bioinformatics are: National Centers for Biomedical Computing, National Center for Simulation of Biological Structures, National Center for the Multiscale Analysis of Genomic and Cellular Networks, National Alliance for Medical Image Computing (NA-MIC), National Center for Biomedical Ontology (NCBO) at Stanford University, Integrate Data for Analysis, Anonymization, and Sharing (IDASH) at the University of California, San Diego. The Canadian government is also ponying up cash for omics research, with the Canada Foundation for Innovation backing several projects as part of a C$30.4 million ($27.6 million) investment in academic research. McGill University scooped the joint-biggest award for a project, C$400,000, to advance its single-cell genomics infrastructure.
- Track 10-1Comparative genomics
- Track 10-2Gene and protein expression
- Track 10-3Biodiversity informatics
- Track 10-4Structural bioinformatics
Next generation sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionized genomic research. The global next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography.
- Track 11-1RNA sequencing
- Track 11-2DNA sequencing
- Track 11-3Sequence assembly
- Track 11-4Sequence analysis
MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. According to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, about 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. MicroRNAs are used as a biomarker for cancer diagnosis and treatment. Some of the major companies operating in the global microRNA market are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exiqon A/S, AstraZeneca Pharmaceuticals LP, Biogen Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Center GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co. Inc., Novartis AG and Sigma-Aldrich. GlaxoSmithKline (GSK) has established collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection.
- Track 12-1Biogenesis
- Track 12-2Cellular functions
- Track 12-3Non-coding RNAs
First, the vast numbers of species and the much larger size of some genomes makes the entire sequencing of all genomes a non-optimal approach for understanding genome structure. Second, within a given species most individuals are genetically distinct in a number of ways. What does it actually mean, for example, to "sequence a human genome"? The genomes of two individuals who are genetically distinct differ with respect to DNA sequence by definition. These two problems, and the potential for other novel applications, have given rise to new approaches which, taken together, constitute the field of comparative genomics.
- Track 13-1Molecular evolution
- Track 13-2Gene Order
- Track 13-3Gene Order
- Track 13-4Regulatory sequences,
Utilitarian Genomics use incomprehensible abundance of information created by genomic transcriptomic tasks to portray quality capacities and cooperation’s. Patterns in Functional Genomics are Affymetrix developed as an early trend-setter around there by imagining a common sense approach to examine quality capacity as a framework.
Functional genomics is a study of molecular biology that attempts to make use of the vast wealth of data produced by genomic projects to describe gene functions and interactions. Functional genomic studies frequently rely on high-throughput technologies such as microarrays image and high-throughput sequencing. Trends in Functional Genomics are Affymetrix emerged as an early innovator in this area by inventing a practical way to analyze gene function as a system.
- Track 14-1Genetic Interaction Mapping
- Track 14-2DNA/Protein interactions
- Track 14-3Microarrays
- Track 14-4Bioinformatics methods for Functional genomics
Pharmacogenomics is a piece of a field called customized solution that means to tweak human services, with choices and medications custom-made to every individual patient inside and out conceivable. Pharmacogenomics and pharmacogenomics manage new developments in the field of customized meds and advancements in modified medication revelation utilizing proteome innovation.
Pharmacogenomics aims to customize health care, with decisions and treatments tailored to each individual patient in every way possible. Genomic testing is still a relatively new development in drug treatment, this field is expanding. Currently, more than 100 drugs have label information regarding pharmacogenomics biomarkers. This information is used to improve the selection and dosage of drugs to treat a wide range of conditions, including cardiovascular disease, lung disease, HIV infection, cancer, arthritis, high cholesterol and depression.
- Track 15-1Pharmacotherapy
- Track 15-2Pharmacokinetics
- Track 15-3Personalized Medicine
- Track 15-4Drug-metabolizing enzymes
Genomic Medicine "as an emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use." Already, genomic medicine is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.
Biomarkers can be trademark organic properties or particles that can be distinguished and measured in parts of the body such as the blood or tissue. Biomarkers can be particular cells, atoms, or qualities, quality items, chemicals, or hormones. Atomic marker is a section of DNA that is connected with a specific area inside of the genome. Atomic markers are utilized as a part of sub-atomic science and biotechnology to distinguish a specific grouping of DNA in a pool of obscure DNA.
Microbial Genomics applies recombinant DNA, DNA sequencing routines, and bioinformatics to succession, gather, and dissect the capacity and structure of genomes in organisms. Amid the previous 10 years, genomics-based methodologies have profoundly affected the field of microbiology and our comprehension of microbial species. In view of their bigger genome sizes, genome sequencing endeavor on growths and unicellular eukaryotes were slower to begin than ventures concentrated on prokaryotes.. A microbial genome program based on rational priorities is needed to make strategic decisions about the appropriation and distribution of funding and resources. OpGen filed plans with the U.S. Securities and Exchange Commission to sell 3.75 million shares in an initial public offering with the goal of securing up to $35.2 million. The Gaithersburg, Md.-based microbial genetics analysis company said it will use the money as working capital and to support increased sales and marketing efforts for its genetic tests for multidrug resistance organisms.
Genome engineering refers to the strategies and techniques developed in recent years for the targeted, specific modification of the genetic information or genome of living organisms. The CRISPR-cas9 system makes gene editing in many organisms and cells like our own egg, sperm or embryo — more efficient, accessible and simple than ever before. These ground-breaking capabilities have spawned discussions surrounding the ethics and applications of the new system, and have garnered significant attention around the world to ensure ethically correct usage.
Genomics research holds the key to meeting many of the challenges of the coming years. At the moment, the biggest challenge is in data analysis. We can generate large amounts of data very inexpensively, but that overwhelms our capacity to understand it. The major challenge of the Genome Research is we need to infuse genomic information into medical practice, which is really hard. There are issues around confidentiality, education, electronic medical records, how to carry genomic information throughout lifespan and make it available to physicians.
Genomics is the study of the genetic material or genomes of an organism. Analysts forecast the Global Genomics market will grow at a CAGR of 11.21% over the period 2013-2018. According to the report, the most important driver of the market is an increase in the demand for consumables. The growing adoption of genetic testing for various applications, especially in regions such as the APAC, and an increase in genetic testing volumes in North America and Western Europe is increasing the demand for consumables.